San Carlos, California, U.S., October 28, 2026
Acurex Biosciences Corporation has received a significant intellectual property milestone for its investigational neurological drug candidate, CU-00048, after the United States Patent and Trademark Office issued a composition-of-matter patent covering the compound. The patent strengthens the company’s development strategy for essential tremor, a neurological movement disorder characterized by involuntary shaking that can interfere with everyday activities. According to the company’s October 26 announcement, U.S. Patent No. 12,760,017 was issued on October 13, 2026, and provides patent protection into 2042 before any potential patent term extension. CU-00048 is an oral, brain-penetrant T-type calcium channel antagonist currently in late-preclinical development. The company is developing the candidate to address the need for effective, well-tolerated treatment options that can support long-term management of essential tremor.
Patent Protection Strengthens CU-00048 Development
The newly issued composition-of-matter patent represents an important step in protecting Acurex Biosciences’ lead drug candidate as it prepares for potential clinical development. Composition-of-matter patents protect the chemical compound itself, subject to the scope of the granted claims, and can provide an important foundation for future pharmaceutical development and commercialization. For Acurex, protection extending into 2042 could strengthen the program’s attractiveness to prospective development partners and investors. The company has indicated that it is discussing potential partnerships and investment opportunities to support the advancement of CU-00048 into human clinical studies. The patent milestone adds intellectual property protection to a program designed around differentiated pharmacology, potential once-daily dosing, and measurable central nervous system target engagement. However, patent protection does not establish clinical efficacy or safety, and the candidate must still undergo appropriate development and evaluation before its potential benefits can be determined in patients.
CU-00048 Targets Essential Tremor Mechanisms
Essential tremor affects millions of people and can cause involuntary shaking of the hands, head, voice, and other body regions. The condition may affect eating, writing, dressing, and other routine activities, creating a substantial need for improved treatment options. CU-00048 targets T-type calcium channels, particularly CaV3.1, which are involved in neuronal excitability and have emerged as an important therapeutic target in essential tremor research. Acurex designed the compound to demonstrate state-dependent channel blockade, with company-reported preclinical findings indicating 9.4-fold greater potency against CaV3.1 channels in the inactivated state than in the relevant comparison state. This approach is intended to preferentially influence overactive neuronal signaling while limiting interference with normal activity. The company also reported that CU-00048 reduced tremor at doses of 1 and 3 mg/kg in a mouse harmaline model of essential tremor. These findings are encouraging at the preclinical research stage, but animal-model results cannot establish that the drug will reduce tremor or be well tolerated in humans. Clinical studies will be necessary to assess its therapeutic potential.
Advertisement
Preclinical Results Support Planned Clinical Evaluation
Beyond its reported tremor-reduction findings, Acurex has highlighted several drug-development characteristics that could support further investigation. Preclinical studies reportedly demonstrated low clearance and high oral bioavailability, properties that may help support the compound’s intended once-daily dosing strategy. The company is also investigating an electroencephalography (EEG) biomarker to measure target engagement during future clinical development. In rat studies, CU-00048 reportedly reduced non-rapid eye movement sleep sigma-band EEG power in association with brain drug levels. Acurex intends to investigate this signal as a potential pharmacodynamic biomarker in a Phase 1 study, where researchers could assess whether the compound produces measurable biological effects in humans. The company believes that this strategy could help evaluate the relationship between drug exposure and central nervous system activity during early development. CU-00048 has not yet been tested in humans, and its safety, tolerability, effective dosage, and clinical benefits remain unestablished. The transition from preclinical research to human trials will therefore be a critical milestone for the program.
For Acurex Biosciences, the new U.S. patent provides a stronger intellectual property position as the company works to advance its neurological drug discovery portfolio. With essential tremor research progressing and T-type calcium channel modulation receiving increased clinical attention, CU-00048 represents an investigational approach aimed at improving treatment options for people living with the disorder. Its future progress will depend on successful clinical evaluation, regulatory requirements, funding, and potential partnerships. The next major milestone will be determining whether CU-00048’s preclinical profile translates into a safe, tolerable, and clinically meaningful treatment in humans.
Source: Acurex Biosciences press release
